Ichnos Glenmark Innovation & AbbVie ink exclusive global licensing agreement for ISB 2001: New York Saturday, July 12, 2025, 12:00 Hrs [IST] IGI Therapeutics SA, a wholly owned su ...

The S&P BSE Sensex also ended lower, falling 0.83% to close at 82,500 points, and registered a weekly loss of over 1.06%.

Global trade tensions just got a whole lot worse! The US is leading the charge with a slew of new tariff announcements that ...

The stock was the top percentage gainer on the Nifty Pharma index, which traded 0.3% higher compared to a 0.8% loss in the ...

Glenmark Pharmaceuticals' shares surged 10% to an all-time high of ₹2,094 following the announcement of an exclusive ...

Glenmark Pharma's exclusive licensing deal with AbbVie for ISB-2001 could be transformative, offering significant upside ...

Indian equity benchmarks posted a second straight weekly loss, weighed down by uncertainty over a potential U.S. trade ...

The antibody, ISB 2001, is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) ...

CHENNAI: Indian equity indices closed sharply lower on Friday (July 11), marked by a sharp sell-off in the IT sector, renewed ...

Shares of Glenmark Pharmaceuticals Ltd ended 14.51 per cent higher on Friday after the firm announced signing an up to USD 2-billion deal with AbbVie to commmercialise its underdevelopment drug aimed ...

Indian equity benchmarks posted a second straight weekly loss, weighed down by uncertainty over a potential U.S. trade deal ...